Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of …
Over the last 12 months, insiders at Atai Life Sciences N.V. have bought $23,120 and sold $521,476 worth of Atai Life Sciences N.V. stock.
On average, over the past 5 years, insiders at Atai Life Sciences N.V. have bought $6.21M and sold $521,476 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Brand Florian (See Remarks) — $23,120.
The last purchase of 20,000 shares for transaction amount of $23,120 was made by Brand Florian (See Remarks) on 2023‑11‑16.
2024-05-16 | Sale | See Remarks | 151,303 0.09% | $1.92 | $290,502 | -30.11% | ||
2024-04-02 | Sale | See Remarks | 61,640 0.0367% | $1.85 | $114,034 | -26.74% | ||
2024-04-02 | Sale | Chief Financial Officer | 27,410 0.0163% | $1.85 | $50,709 | -26.74% | ||
2024-04-02 | Sale | Chief Business Officer | 35,801 0.0213% | $1.85 | $66,232 | -26.74% | ||
2023-11-16 | See Remarks | 20,000 0.0125% | $1.16 | $23,120 | +41.99% | |||
2023-09-13 | See Remarks | 40,000 0.0242% | $1.45 | $57,968 | +5.67% | |||
2023-03-29 | 10 percent owner | 1.21M 0.6461% | $1.32 | $1.6M | +8.33% | |||
2023-03-29 | See Remarks | 70,000 0.0418% | $1.48 | $103,558 | +8.33% | |||
2022-04-28 | 21,900 0.0144% | $4.47 | $97,801 | -28.96% | ||||
2022-04-26 | 19,803 0.013% | $4.64 | $91,939 | -31.30% | ||||
2022-04-22 | 52,820 0.0346% | $4.83 | $254,962 | -33.79% | ||||
2022-04-20 | 68,688 0.0434% | $4.95 | $340,040 | -37.52% | ||||
2022-04-18 | 54,322 0.0353% | $5.11 | $277,656 | -37.38% | ||||
2022-04-14 | 4,967 0.0031% | $5.19 | $25,779 | -39.38% | ||||
2022-04-12 | 55,197 0.0356% | $4.88 | $269,560 | -33.94% | ||||
2022-04-08 | 57,689 0.0364% | $4.81 | $277,640 | -33.54% | ||||
2021-06-22 | 10 percent owner | 700,000 0.4218% | $15.00 | $10.5M | -57.97% | |||
2021-06-22 | 700,000 0.4218% | $15.00 | $10.5M | -57.97% | ||||
2021-06-22 | director | 4,666 0.0028% | $15.00 | $69,990 | -57.97% | |||
2021-06-22 | Chief Financial Officer | 4,666 0.0028% | $15.00 | $69,990 | -57.97% |
Brand Florian | See Remarks | 328697 0.1959% | $1.19 | 4 | 1 | <0.0001% |
Rao Srinivas | See Remarks | 113360 0.0676% | $1.19 | 1 | 1 | <0.0001% |
Apeiron Investment Group Ltd. | 10 percent owner | 32086697 19.1221% | $1.19 | 2 | 0 | <0.0001% |
Auerbach Michael | director | 5564474 3.3162% | $1.19 | 1 | 0 | <0.0001% |
Angermayer Christian | 1799302 1.0723% | $1.19 | 9 | 0 | <0.0001% |
Morgan Stanley | $5.26M | 1.59 | 2.67M | -15.21% | -$942,917.27 | <0.0001 | |
Millennium Management LLC | $4.37M | 1.32 | 2.22M | +191.36% | +$2.87M | <0.01 | |
BlackRock | $2.76M | 0.84 | 1.4M | +3.03% | +$81,227.04 | <0.0001 | |
Marshall Wace | $1.56M | 0.47 | 793,839 | +2.31% | +$35,361.50 | <0.01 | |
Brown University | $1.42M | 0.43 | 718,500 | 0% | +$0 | 0.59 |